Change in expression of vesicular protein synapsin II by chronic treatment with D2 allosteric modulator PAOPA.

Abstract

The hallmark symptoms of schizophrenia include profound disturbances in thought, perception, cognition etc., which negatively impacts an individual's quality of life. Current antipsychotic drugs are not effective in treating all symptoms of this disorder, and often cause severe movement and metabolic side effects. Consequently, there remains a strong impetus to develop safer and more efficacious therapeutics for patients, as well as elucidating the etiology of schizophrenia. Previous work in our lab has introduced a novel candidate for the treatment of this disease: the dopamine D2 receptor (D2R) allosteric modulator, 3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA). We have previously shown that PAOPA, by selectively modulating D2R, can ameliorate schizophrenia-like symptoms in animal models, although the precise mechanism is presently not understood. Synapsin II is a presynaptic vesicular protein which has been strongly implicated in schizophrenia, as it is reduced in the prefrontal cortex of patients, and knockdown of this protein elicits schizophrenia-like phenotypes in animal models. Given the therapeutic effects of PAOPA and the role of synapsin II in schizophrenia, the objective of this study was to investigate the effect of chronic administration of PAOPA (45 days) on neuronal synapsin II protein expression in rodents. Immunoblot results revealed that the synapsin IIa, but not the IIb isoform, was increased in the dopaminergic regions of the striatum, nucleus accumbens, and medial prefrontal cortex. The results of this study implicate a role for modulation of synapsin II as a possible therapeutic mechanism of action for potential antipsychotic drug PAOPA.

• Authors: Dipannita Basu, Yuxin Tian, Patricia Hui, Jayant Bhandari, Rodney L Johnson, Ram K Mishra
• Journal: Peptides (Peptides) Vol. 66 Pg. 58-62 (Apr 2015) ISSN: 1873-5169 [Electronic] United States
• PMID: 25703303 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Antipsychotic Agents
• Pyrrolidinones
• Synapsins
• 3-(N-prolylamine)-2-oxo-1-pyrrolidineacetamide

Topics

• Animals
• Antipsychotic Agents (pharmacology)
• Blotting, Western
• Cerebellum (drug effects, metabolism)
• Male
• Nucleus Accumbens (drug effects, metabolism)
• Prefrontal Cortex (drug effects, metabolism)
• Pyrrolidinones (pharmacology)
• Rats
• Rats, Sprague-Dawley
• Synapsins (metabolism)